Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 19620961.
- Also identified by DOI 10.1038/nm.1991 and PMC identifier 2756115.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
Medical subject headings
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adenoviridae
- HIV-1